{"url_path":"/sec/tpst/8-k/2026-06-04/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-257684-index.html","accession_number":"0001193125-26-257684","cik":"0001544227","ticker":"TPST","issuer_name":"Tempest Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-257684-index.html","primary_entity_key":"0001544227","primary_entity_name":"Tempest Therapeutics, Inc."},"word_count":119,"has_tables":true,"body_markdown":"Item 7.01.\n\nRegulation FD Disclosure.\n\nOn June 4, 2026, the Company issued a press release entitled “Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information furnished in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly provided by specific reference in such a filing."}